Serum potassium and heart failure: association, causation, and clinical implications
Related Experiment Video
Updated: Dec 4, 2025
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Dimitrios Sfairopoulos1, Angelos Arseniou1, Panagiotis Korantzopoulos2
1First Department of Cardiology, University of Ioannina Medical School, 45100, Ioannina, Greece.
Insights
Hypokalemia, not hyperkalemia, is causally linked to poor heart failure outcomes. Maintaining serum potassium between 4.0-5.0 mmol/L is crucial for managing heart failure patients and optimizing treatment.
Area of Science:
- Cardiology
- Nephrology
- Clinical Medicine
Background:
- Dyskalemia (hypokalemia and hyperkalemia) is common in heart failure (HF) patients.
- Both hypo- and hyperkalemia are associated with adverse outcomes in HF.
- The causal relationship between dyskalemia and HF outcomes requires investigation.
Purpose of the Study:
- To investigate the causal relationship between dyskalemia and adverse clinical outcomes in heart failure.
- To evaluate the impact of potassium levels on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in HF.
- To establish optimal serum potassium targets for HF management.
Main Methods:
- Literature review and application of the Bradford Hill criteria for causation.
- Analysis of studies examining serum potassium levels and clinical outcomes in HF.
- Assessment of hyperkalemia's impact on RAASi efficacy in HF patients.
Main Results:
- Hypokalemia and low-normal potassium (< 4.0 mmol/L) show a cause-and-effect association with adverse HF outcomes.
- Hyperkalemia (> 5.0 mmol/L) does not appear to have a causal link to adverse HF outcomes.
- Hyperkalemia frequently limits beneficial RAASi therapy in HF patients.
Conclusions:
- Hypokalemia is a causal factor for poor outcomes in heart failure.
- Maintaining serum potassium within 4.0-5.0 mmol/L is recommended for HF patients.
- Correcting hyperkalemia may indirectly benefit HF patients by enabling optimal RAASi titration.
Abstract:
Dyskalemia (hypo- and hyperkalemia) is a common clinical encounter in patients with heart failure (HF), linked to underlying pathophysiologic alterations, pharmacological treatments, and concomitant comorbidities. Both hypo- and hyperkalemia have been associated with a poor outcome in HF. However, it is not known if this association is causal. In order to investigate this relation, we implemented the Bradford Hill criteria for causation examining the available literature. Of note, hypokalemia and low-normal potassium levels (serum potassium < 4.0 mmol/L) appear to be associated with adverse clinical outcomes in HF in a cause-and-effect manner. Conversely, a cause-and-effect relationship between hyperkalemia (serum potassium > 5.0 mmol/L) and adverse clinical outcomes in HF appears unlikely. We also examined the benefits of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy uptitration in patients with HF and reduced ejection fraction. In fact, hyperkalemia often limits RAASi use, thereby negating or mitigating their clinical benefits. Finally, serum potassium levels in HF should be maintained within the range of 4.0-5.0 mmol/L, and although the correction of hyperkalemia does not appear to improve clinical outcomes per se, it may enable the optimal titration of RAASi, offering indirect clinical benefit.
More Related Videos
Related Concept Videos
01:27Heart Failure I: Introduction
01:22Heart Failure Drugs: Diuretics
01:17Pathophysiology of Heart Failure
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:26Heart Failure Drugs: Inotropic Agents
01:29Heart Failure II: Pathophysiology